Benzofuro[3,2-f][1]benzopyrans: a new class of antitubercular agents. 2006

Soizic Prado, and Hervé Ledeit, and Sylvie Michel, and Michel Koch, and Jacques Christian Darbord, and Stewart T Cole, and François Tillequin, and Priscille Brodin
Laboratoire de Pharmacognosie, UMR/CNRS 8638, 4 avenue de l'Observatoire, 75006 Paris, France.

Alkylation of 2-hydroxydibenzofuran with 3-chloro-3-methyl-1-butyne, followed by Claisen rearrangement, gave access to 3,3-dimethyl-3Hbenzofuro[3,2-f][1]-benzopyran. Several derivatives modified at the pyran 1,2-double bond were prepared, including the corresponding dihydro compound and (+/-)-cis-diol, which was converted into diacetate and cyclic carbonate upon acylation. Both 3,3-dimethyl-3Hbenzofuro[3,2-f][1]benzopyran and 1,2-dihydro-3,3-dimethyl-3Hbenzofuro[3,2-f][1]benzopyran displayed significant activities when tested against Mycobacterium tuberculosis H37Rv and Beijing strains, with MIC99 in the range of 1-10 microg/ml. Further biological studies demonstrated good activities against drug-resistant mycobacterial strains. These compounds appear as promising specific antitubercular agents, since they exhibited neither significant cytotoxicity against mammal cells, nor effect on the growth of various bacteria and fungi.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D009169 Mycobacterium tuberculosis A species of gram-positive, aerobic bacteria that produces TUBERCULOSIS in humans, other primates, CATTLE; DOGS; and some other animals which have contact with humans. Growth tends to be in serpentine, cordlike masses in which the bacilli show a parallel orientation. Mycobacterium tuberculosis H37Rv
D002176 Candida albicans A unicellular budding fungus which is the principal pathogenic species causing CANDIDIASIS (moniliasis). Candida albicans var. stellatoidea,Candida stellatoidea,Dematium albicans,Monilia albicans,Myceloblastanon albicans,Mycotorula albicans,Parasaccharomyces albicans,Procandida albicans,Procandida stellatoidea,Saccharomyces albicans,Syringospora albicans
D004353 Drug Evaluation, Preclinical Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications. Drug Screening,Evaluation Studies, Drug, Pre-Clinical,Drug Evaluation Studies, Preclinical,Drug Evaluations, Preclinical,Evaluation Studies, Drug, Preclinical,Evaluation, Preclinical Drug,Evaluations, Preclinical Drug,Medicinal Plants Testing, Preclinical,Preclinical Drug Evaluation,Preclinical Drug Evaluations,Drug Screenings,Screening, Drug,Screenings, Drug
D000995 Antitubercular Agents Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy. Anti-Tuberculosis Agent,Anti-Tuberculosis Agents,Anti-Tuberculosis Drug,Anti-Tuberculosis Drugs,Antitubercular Agent,Antitubercular Drug,Tuberculostatic Agent,Tuberculostatic Agents,Antitubercular Drugs,Agent, Anti-Tuberculosis,Agent, Antitubercular,Agent, Tuberculostatic,Anti Tuberculosis Agent,Anti Tuberculosis Agents,Anti Tuberculosis Drug,Anti Tuberculosis Drugs,Drug, Anti-Tuberculosis,Drug, Antitubercular
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular
D020102 Mycobacterium smegmatis A rapid-growing, nonphotochromogenic species of MYCOBACTERIUM originally isolated from human smegma and found also in soil and water. (From Dorland, 28th ed)
D039903 Actinobacteria Class of BACTERIA with diverse morphological properties. Strains of Actinobacteria show greater than 80% 16S rDNA/rRNA sequence similarity among each other and also the presence of certain signature nucleotides. (Stackebrandt E. et al, Int. J. Syst. Bacteriol. (1997) 47:479-491) Actinomycete,Actinomycetes,Gram-Positive Bacteria, High G+C,High G+C Gram-Positive Bacteria

Related Publications

Soizic Prado, and Hervé Ledeit, and Sylvie Michel, and Michel Koch, and Jacques Christian Darbord, and Stewart T Cole, and François Tillequin, and Priscille Brodin
March 1998, Ceska a Slovenska farmacie : casopis Ceske farmaceuticke spolecnosti a Slovenske farmaceuticke spolecnosti,
Soizic Prado, and Hervé Ledeit, and Sylvie Michel, and Michel Koch, and Jacques Christian Darbord, and Stewart T Cole, and François Tillequin, and Priscille Brodin
October 2012, Bioorganic & medicinal chemistry letters,
Soizic Prado, and Hervé Ledeit, and Sylvie Michel, and Michel Koch, and Jacques Christian Darbord, and Stewart T Cole, and François Tillequin, and Priscille Brodin
January 2019, Current topics in medicinal chemistry,
Soizic Prado, and Hervé Ledeit, and Sylvie Michel, and Michel Koch, and Jacques Christian Darbord, and Stewart T Cole, and François Tillequin, and Priscille Brodin
October 2010, Bioorganic & medicinal chemistry letters,
Soizic Prado, and Hervé Ledeit, and Sylvie Michel, and Michel Koch, and Jacques Christian Darbord, and Stewart T Cole, and François Tillequin, and Priscille Brodin
February 2010, European journal of medicinal chemistry,
Soizic Prado, and Hervé Ledeit, and Sylvie Michel, and Michel Koch, and Jacques Christian Darbord, and Stewart T Cole, and François Tillequin, and Priscille Brodin
March 2020, European journal of medicinal chemistry,
Soizic Prado, and Hervé Ledeit, and Sylvie Michel, and Michel Koch, and Jacques Christian Darbord, and Stewart T Cole, and François Tillequin, and Priscille Brodin
September 2000, Die Pharmazie,
Soizic Prado, and Hervé Ledeit, and Sylvie Michel, and Michel Koch, and Jacques Christian Darbord, and Stewart T Cole, and François Tillequin, and Priscille Brodin
July 1973, Journal of medicinal chemistry,
Soizic Prado, and Hervé Ledeit, and Sylvie Michel, and Michel Koch, and Jacques Christian Darbord, and Stewart T Cole, and François Tillequin, and Priscille Brodin
September 1988, Die Pharmazie,
Soizic Prado, and Hervé Ledeit, and Sylvie Michel, and Michel Koch, and Jacques Christian Darbord, and Stewart T Cole, and François Tillequin, and Priscille Brodin
October 1968, Revista clinica espanola,
Copied contents to your clipboard!